Intratio
Loading...
Skip to main content
Model output · Signal date 2026-10-14

Onemednet Corp (ONMD) Stock Forecast Oct. 14, 2026

Analysis updated on Oct. 14, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq

Follow Unlock full AI forecasts
Rating · 90D Neutral Alpha
90-day forecast Sign up free to reveal
30-day forecast Alpha
Rank in coverage Middle 30% of 5379 stocks scored
Rank correlation · 90D n/a No per-ticker sample yet
Market Cap $24M small-cap · #10 of 12 peers
Summary

Onemednet Corp (ONMD) stock forecast summary

On Oct. 14, 2026, ONMD is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5379 stocks scored that day.

Onemednet Corp is a small-cap company with a market capitalization of $24M. It ranks number 10 by market capitalization among the 12 Services-Commercial Physical & Biological Research issuers in our coverage with a current forecast.

A per-ticker accuracy statistic for ONMD is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.3%, buy ≥ +0.5%, sell < -0.5%, strong sell < -1.6% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-13 signals)

A free account shows the exact forecast, rating and rank of 3 tickers you follow, ONMD included.

Follow ONMD free
Price

ONMD price chart and AI forecast

ONMD
Cross-section · 2026-10-13

How ONMD ranks among 5379 stocks

90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).

Fundamentals

Onemednet Corp (ONMD) fundamentals

Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Services-Commercial Physical & Biological Research peers listed below that report each metric.

Reported net income does not reconcile with earnings per share and the share count, so net-income-based ratios are withheld.

Valuation & Market

MetricONMDIndustry medianRank
Market Cap $24M $1.12B 10/12
EPS $-0.10 – –

Profitability & Margins

MetricONMDIndustry medianRank
Gross Margin -63.2% 33.0% 6/7
Operating Margin -875.3% -125.8% 11/13
EBT Margin -383.4% -114.8% 11/13

Financial Health

MetricONMDIndustry medianRank
Current Ratio 0.28x 0.78x 12/16
Interest Coverage -255.2x -2.7x 10/13
Working Capital -$3M -$1M 11/15

Cash Flow

MetricONMDIndustry medianRank
Operating Cash Flow -$9M -$280K 10/15

Income Statement

MetricONMDIndustry medianRank
Operating Income -$12M $0.00M 11/15
R&D Expense $2M $17M 5/7
SG&A Expense $14M $41M 8/12
Cost of Goods Sold $2M $4M 5/8

Dividend & Shareholder Information

MetricONMDIndustry medianRank
Shares Outstanding 6M – –

Balance Sheet Highlights (USD millions)

Total Current Assets$1M
Cash & Short-term Investments$360K
Accounts Receivable$660K
Total Liabilities$5M
Quarterly Financial Reports

ONMD quarterly financials and insider trading

Industry Peers · Services-Commercial Physical & Biological Research

Onemednet Corp (ONMD) industry peers

Companies classified under the same SEC industry code as Onemednet Corp (Services-Commercial Physical & Biological Research): 16 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.

Reveal all forecasts · See exact % predictions for all competitors

Sign up free
Company 90-Day AI Forecast (Alpha) Market Cap P/E Ratio P/B Ratio
ONMD Onemednet Corp ▶ $24M – –
IQV Iqvia Holdings Inc. ▼ $43.51B 32.6x 7.3x
INCY Incyte Corp ▼ $21.70B 17.5x 4.5x
MEDP Medpace Holdings, Inc. ▶ $17.02B 34.6x 39.2x
CRL Charles River Laboratories International, Inc. ▶ $14.27B – 5.0x
ICLR Icon Plc ▶ $12.68B – 1.4x
ABSI Absci Corp ▲ $1.56B – 7.9x
OABI Omniab, Inc. ▲ $683M – 2.6x
NRC Nrc Health ▲ $446M – –
MXCT Maxcyte, Inc. ▲ $100M – 0.6x
VSBC Vitaspring Biomedical Co. Ltd. ▼ $7M – –
BUDZ Weed, Inc. ▲ $3M – –
BIAF Bioaffinity Technologies, Inc. ▼ N/A – –
CBIH Cannabis Bioscience International Holdings, Inc. ▼ N/A – –
FOXO Foxo Technologies Inc. ▼ N/A – –
ISPC Ispecimen Inc. ▼ N/A – –

Where ONMD sits on the market map

Industrial Applications and Services · Services-Commercial Physical & Biological Research
Explore the map →
News

Onemednet Corp (ONMD) stock news

Loading...

FAQ

Onemednet Corp (ONMD) stock forecast FAQ

What is the Onemednet Corp (ONMD) stock forecast?

On Oct. 14, 2026, ONMD is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5379 stocks scored that day.

How accurate are Onemednet Corp stock predictions?

A per-ticker accuracy statistic for ONMD is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

How often are Onemednet Corp forecasts updated?

Onemednet Corp forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 14, 2026.

Which companies are Onemednet Corp's industry peers?

16 issuers in our coverage, ONMD included, share the SEC industry code Services-Commercial Physical & Biological Research. The largest are: Iqvia Holdings Inc. (IQV), Incyte Corp (INCY), Medpace Holdings, Inc. (MEDP), Charles River Laboratories International, Inc. (CRL), Icon Plc (ICLR), Absci Corp (ABSI).

This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.